JP Patent

JP6091716B2 — オレキシン受容体アンタゴニストとしての（ｓ）−（２−（６−クロロ−７−メチル−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−２−メチルピロリジン−１−イル）（５−メトキシ−２−（２ｈ−１，２，３−トリアゾール−２−イル）フェニル）メタノンの塩結晶形

Assigned to Actelion Pharmaceuticals Ltd · Expires 2017-03-08 · 9y expired

What this patent protects

Patent listed against daridorexant-hydrochloride.

Drugs covered by this patent

daridorexant-hydrochloride (DARIDOREXANT HYDROCHLORIDE)

Patent Metadata

Patent number: JP6091716B2
Jurisdiction: JP
Classification: —
Expires: 2017-03-08
Drug substance claim: No
Drug product claim: No
Assignee: Actelion Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.